Image de couverture de livre

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Jiajie He, Fan Xia, Lingzi Yu, Rui Zou, Qian Zhu, Xiao Zhang, Junhong Li, Danqing Kong, Depei Wu, Zhengming Jin, Nana Ping, Changju Qu
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Hematological Oncology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Peripheral T‐Cell Lymphoma: What's Next?
par: Sang Eun Yoon, et autres
Publié: (2025)

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First‐Line Chemotherapy in Patients With Lymphoma
par: Charlotte Nørregaard Grønset, et autres
Publié: (2025)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
par: Masahito Tokunaga, et autres
Publié: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
par: Jinyan Xiao, et autres
Publié: (2025)

Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy
par: Nan Wang, et autres
Publié: (2024)

Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
par: Robin Noel, et autres
Publié: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
par: Oskar Steinbrecher, et autres
Publié: (2024)

Re: Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
par: Theodoros P. Vassilakopoulos, et autres
Publié: (2025)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
par: Yoshikazu Ikoma, et autres
Publié: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Publié: (2026)

Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
par: Prokop Vodicka, et autres
Publié: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
par: J.T. Jutzi, et autres
Publié: (2025)

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
par: Alexandra Zduniak, et autres
Publié: (2025)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
par: Yan Li, et autres
Publié: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Publié: (2025)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
par: Rui Sun, et autres
Publié: (2026)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
par: Emil Kumar, et autres
Publié: (2025)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
par: Rafaella Cabral Samico, et autres
Publié: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
par: Hazim S. Ababneh, et autres
Publié: (2024)

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
par: Peter Borchmann, et autres
Publié: (2025)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
par: Giacomo Loseto, et autres
Publié: (2025)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
par: Yue Zhao, et autres
Publié: (2025)

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches
par: Sonali M. Smith
Publié: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
par: Gabriela Forestieri, et autres
Publié: (2024)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
par: Simone Ferrero, et autres
Publié: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
par: Chuanming Lin, et autres
Publié: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
par: Meirav Kedmi, et autres
Publié: (2024)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
par: Monia Marchetti, et autres
Publié: (2025)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
par: Allison M. Bock, et autres
Publié: (2024)

Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
par: M. Picardi, et autres
Publié: (2024)

Causal Associations of Gut Microbiota Species With Lymphoma: A Two‐Sample Mendelian Randomization Study
par: Mei Li, et autres
Publié: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
par: Lotte Nygård, et autres
Publié: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
par: Juliette Penichoux, et autres
Publié: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
par: Yutaka Shimazu, et autres
Publié: (2025)

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience
par: Hala Bekhit, et autres
Publié: (2025)

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
par: James R. Cerhan, et autres
Publié: (2025)

Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials
Publié: (2025)

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study
par: John L. Vaughn, et autres
Publié: (2026)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
par: Minna Harmanen, et autres
Publié: (2025)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
par: Youwen Zhu, et autres
Publié: (2026)